Medical Care

Global PD-L1 Biomarker Testing Market Research Report 2025

The global market for PD-L1 Biomarker Testing was valued at US$ 2815 million in the year 2024 and is projected to reach a revised size of US$ 27020 million by 2031, growing at a CAGR of 38.7% during the forecast period.
PD-L1 Biomarker Testing measures the amount of PDL1 on cancer cells. PDL1 is a protein that helps keep immune cells from attacking nonharmful cells in the body. Normally, the immune system fights foreign substances like viruses and bacteria, and not your own healthy cells. Some cancer cells have high amounts of PDL1. This allows the cancer cells to "trick" the immune system, and avoid being attacked as foreign, harmful substances. Current PD-L1 testing is based on immunohistochemistry (IHC) methods. Immunohistochemistry (IHC) is the process whereby antibodies are used to detect proteins (antigens) in cells within a tissue section (for instance liver, pancreas or the heart). PD-L1 is a ligand that binds to PD-1 (programmed cell death-1), expressed on activated T cells, to evade anti-tumor responses. PD-L1 plays a role in inhibiting T cell activation and proliferation and has emerged as an important target in cancer treatment. PD-L1 protein detection by immunohistochemistry (IHC) testing is widely used as a predictive biomarker assay for anti–PD-1/PD-L1 therapies. PDL1 testing is used to find out if you have a cancer that may benefit from immunotherapy.
The PD‑L1 biomarker testing market is being propelled by the rapid expansion of immune checkpoint inhibitor therapies, particularly those targeting the PD‑1/PD‑L1 axis, which have shown remarkable clinical success in treating various advanced cancers—spurring widespread demand for stratifying patients based on PD‑L1 expression to optimize treatment outcomes. Additionally, the shift toward precision medicine has heightened the importance of molecular diagnostics. Clinicians and pharmaceutical developers are increasingly emphasizing personalized approaches, using PD‑L1 testing to guide therapeutic decisions and enable companion diagnostics—especially as diagnostic technologies advance to include automated IHC systems, NGS platforms, and AI-enhanced analysis .
Despite these positive trends, the PD‑L1 testing landscape faces significant obstacles due to a lack of standardization across protocols, assay clones, scoring systems, and cut-off thresholds. This inconsistency manifests in discordant results (with variability rates reported between 19–32% across different assays), undermining diagnostic reliability and complicating clinical decision-making. Moreover, high costs associated with advanced testing techniques (IHC, NGS) and uneven reimbursement frameworks create economic barriers, particularly in developing regions, impeding broad accessibility and exacerbating healthcare disparities.
The classification of PD-L1 Biomarker Testing includes PD-L1 (22C3), PD-L1 (28-8), PD-L1 (SP142), PD-L1 (SP263) and Other, and the revenue proportion of PD-L1 (22C3) in 2024 is about 21.68%. PD-L1 Biomarker Testing is widely used in Hospital and Diagnostic Laboratories. The most proportion of PD-L1 Biomarker Testing is Hospital, and the proportion in 2024 is about 52.7%.
This report aims to provide a comprehensive presentation of the global market for PD-L1 Biomarker Testing, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding PD-L1 Biomarker Testing.
The PD-L1 Biomarker Testing market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global PD-L1 Biomarker Testing market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the PD-L1 Biomarker Testing companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Agilent Technologies
Roche
Merck
Bristol-Myers Squibb
AstraZeneca
Ono Pharmaceutical
Regeneron
Innovent
Hengrui Medicine
Junshi Biosciences
Segment by Type
PD-L1 (22C3)
PD-L1(28-8)
PD-L1 (SP142)
PD-L1 (SP263)
Other
Segment by Application
Hospital
Diagnostic Center
Others
By Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia & New Zealand
Europe
Germany
France
U.K.
Italy
Ireland
Russia
Rest of Europe
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Israel
United Arab Emirates (UAE)
Saudi Arabia
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of PD-L1 Biomarker Testing company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global PD-L1 Biomarker Testing Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 PD-L1 (22C3)
1.2.3 PD-L1(28-8)
1.2.4 PD-L1 (SP142)
1.2.5 PD-L1 (SP263)
1.2.6 Other
1.3 Market by Application
1.3.1 Global PD-L1 Biomarker Testing Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Diagnostic Center
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global PD-L1 Biomarker Testing Market Perspective (2020-2031)
2.2 Global PD-L1 Biomarker Testing Growth Trends by Region
2.2.1 Global PD-L1 Biomarker Testing Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 PD-L1 Biomarker Testing Historic Market Size by Region (2020-2025)
2.2.3 PD-L1 Biomarker Testing Forecasted Market Size by Region (2026-2031)
2.3 PD-L1 Biomarker Testing Market Dynamics
2.3.1 PD-L1 Biomarker Testing Industry Trends
2.3.2 PD-L1 Biomarker Testing Market Drivers
2.3.3 PD-L1 Biomarker Testing Market Challenges
2.3.4 PD-L1 Biomarker Testing Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top PD-L1 Biomarker Testing Players by Revenue
3.1.1 Global Top PD-L1 Biomarker Testing Players by Revenue (2020-2025)
3.1.2 Global PD-L1 Biomarker Testing Revenue Market Share by Players (2020-2025)
3.2 Global Top PD-L1 Biomarker Testing Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by PD-L1 Biomarker Testing Revenue
3.4 Global PD-L1 Biomarker Testing Market Concentration Ratio
3.4.1 Global PD-L1 Biomarker Testing Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by PD-L1 Biomarker Testing Revenue in 2024
3.5 Global Key Players of PD-L1 Biomarker Testing Head office and Area Served
3.6 Global Key Players of PD-L1 Biomarker Testing, Product and Application
3.7 Global Key Players of PD-L1 Biomarker Testing, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 PD-L1 Biomarker Testing Breakdown Data by Type
4.1 Global PD-L1 Biomarker Testing Historic Market Size by Type (2020-2025)
4.2 Global PD-L1 Biomarker Testing Forecasted Market Size by Type (2026-2031)
5 PD-L1 Biomarker Testing Breakdown Data by Application
5.1 Global PD-L1 Biomarker Testing Historic Market Size by Application (2020-2025)
5.2 Global PD-L1 Biomarker Testing Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America PD-L1 Biomarker Testing Market Size (2020-2031)
6.2 North America PD-L1 Biomarker Testing Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America PD-L1 Biomarker Testing Market Size by Country (2020-2025)
6.4 North America PD-L1 Biomarker Testing Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe PD-L1 Biomarker Testing Market Size (2020-2031)
7.2 Europe PD-L1 Biomarker Testing Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe PD-L1 Biomarker Testing Market Size by Country (2020-2025)
7.4 Europe PD-L1 Biomarker Testing Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific PD-L1 Biomarker Testing Market Size (2020-2031)
8.2 Asia-Pacific PD-L1 Biomarker Testing Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific PD-L1 Biomarker Testing Market Size by Region (2020-2025)
8.4 Asia-Pacific PD-L1 Biomarker Testing Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America PD-L1 Biomarker Testing Market Size (2020-2031)
9.2 Latin America PD-L1 Biomarker Testing Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America PD-L1 Biomarker Testing Market Size by Country (2020-2025)
9.4 Latin America PD-L1 Biomarker Testing Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa PD-L1 Biomarker Testing Market Size (2020-2031)
10.2 Middle East & Africa PD-L1 Biomarker Testing Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa PD-L1 Biomarker Testing Market Size by Country (2020-2025)
10.4 Middle East & Africa PD-L1 Biomarker Testing Market Size by Country (2026-2031)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Agilent Technologies
11.1.1 Agilent Technologies Company Details
11.1.2 Agilent Technologies Business Overview
11.1.3 Agilent Technologies PD-L1 Biomarker Testing Introduction
11.1.4 Agilent Technologies Revenue in PD-L1 Biomarker Testing Business (2020-2025)
11.1.5 Agilent Technologies Recent Development
11.2 Roche
11.2.1 Roche Company Details
11.2.2 Roche Business Overview
11.2.3 Roche PD-L1 Biomarker Testing Introduction
11.2.4 Roche Revenue in PD-L1 Biomarker Testing Business (2020-2025)
11.2.5 Roche Recent Development
11.3 Merck
11.3.1 Merck Company Details
11.3.2 Merck Business Overview
11.3.3 Merck PD-L1 Biomarker Testing Introduction
11.3.4 Merck Revenue in PD-L1 Biomarker Testing Business (2020-2025)
11.3.5 Merck Recent Development
11.4 Bristol-Myers Squibb
11.4.1 Bristol-Myers Squibb Company Details
11.4.2 Bristol-Myers Squibb Business Overview
11.4.3 Bristol-Myers Squibb PD-L1 Biomarker Testing Introduction
11.4.4 Bristol-Myers Squibb Revenue in PD-L1 Biomarker Testing Business (2020-2025)
11.4.5 Bristol-Myers Squibb Recent Development
11.5 AstraZeneca
11.5.1 AstraZeneca Company Details
11.5.2 AstraZeneca Business Overview
11.5.3 AstraZeneca PD-L1 Biomarker Testing Introduction
11.5.4 AstraZeneca Revenue in PD-L1 Biomarker Testing Business (2020-2025)
11.5.5 AstraZeneca Recent Development
11.6 Ono Pharmaceutical
11.6.1 Ono Pharmaceutical Company Details
11.6.2 Ono Pharmaceutical Business Overview
11.6.3 Ono Pharmaceutical PD-L1 Biomarker Testing Introduction
11.6.4 Ono Pharmaceutical Revenue in PD-L1 Biomarker Testing Business (2020-2025)
11.6.5 Ono Pharmaceutical Recent Development
11.7 Regeneron
11.7.1 Regeneron Company Details
11.7.2 Regeneron Business Overview
11.7.3 Regeneron PD-L1 Biomarker Testing Introduction
11.7.4 Regeneron Revenue in PD-L1 Biomarker Testing Business (2020-2025)
11.7.5 Regeneron Recent Development
11.8 Innovent
11.8.1 Innovent Company Details
11.8.2 Innovent Business Overview
11.8.3 Innovent PD-L1 Biomarker Testing Introduction
11.8.4 Innovent Revenue in PD-L1 Biomarker Testing Business (2020-2025)
11.8.5 Innovent Recent Development
11.9 Hengrui Medicine
11.9.1 Hengrui Medicine Company Details
11.9.2 Hengrui Medicine Business Overview
11.9.3 Hengrui Medicine PD-L1 Biomarker Testing Introduction
11.9.4 Hengrui Medicine Revenue in PD-L1 Biomarker Testing Business (2020-2025)
11.9.5 Hengrui Medicine Recent Development
11.10 Junshi Biosciences
11.10.1 Junshi Biosciences Company Details
11.10.2 Junshi Biosciences Business Overview
11.10.3 Junshi Biosciences PD-L1 Biomarker Testing Introduction
11.10.4 Junshi Biosciences Revenue in PD-L1 Biomarker Testing Business (2020-2025)
11.10.5 Junshi Biosciences Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global PD-L1 Biomarker Testing Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of PD-L1 (22C3)
Table 3. Key Players of PD-L1(28-8)
Table 4. Key Players of PD-L1 (SP142)
Table 5. Key Players of PD-L1 (SP263)
Table 6. Key Players of Other
Table 7. Global PD-L1 Biomarker Testing Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global PD-L1 Biomarker Testing Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 9. Global PD-L1 Biomarker Testing Market Size by Region (2020-2025) & (US$ Million)
Table 10. Global PD-L1 Biomarker Testing Market Share by Region (2020-2025)
Table 11. Global PD-L1 Biomarker Testing Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 12. Global PD-L1 Biomarker Testing Market Share by Region (2026-2031)
Table 13. PD-L1 Biomarker Testing Market Trends
Table 14. PD-L1 Biomarker Testing Market Drivers
Table 15. PD-L1 Biomarker Testing Market Challenges
Table 16. PD-L1 Biomarker Testing Market Restraints
Table 17. Global PD-L1 Biomarker Testing Revenue by Players (2020-2025) & (US$ Million)
Table 18. Global PD-L1 Biomarker Testing Market Share by Players (2020-2025)
Table 19. Global Top PD-L1 Biomarker Testing Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in PD-L1 Biomarker Testing as of 2024)
Table 20. Ranking of Global Top PD-L1 Biomarker Testing Companies by Revenue (US$ Million) in 2024
Table 21. Global 5 Largest Players Market Share by PD-L1 Biomarker Testing Revenue (CR5 and HHI) & (2020-2025)
Table 22. Global Key Players of PD-L1 Biomarker Testing, Headquarters and Area Served
Table 23. Global Key Players of PD-L1 Biomarker Testing, Product and Application
Table 24. Global Key Players of PD-L1 Biomarker Testing, Date of Enter into This Industry
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global PD-L1 Biomarker Testing Market Size by Type (2020-2025) & (US$ Million)
Table 27. Global PD-L1 Biomarker Testing Revenue Market Share by Type (2020-2025)
Table 28. Global PD-L1 Biomarker Testing Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 29. Global PD-L1 Biomarker Testing Revenue Market Share by Type (2026-2031)
Table 30. Global PD-L1 Biomarker Testing Market Size by Application (2020-2025) & (US$ Million)
Table 31. Global PD-L1 Biomarker Testing Revenue Market Share by Application (2020-2025)
Table 32. Global PD-L1 Biomarker Testing Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 33. Global PD-L1 Biomarker Testing Revenue Market Share by Application (2026-2031)
Table 34. North America PD-L1 Biomarker Testing Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. North America PD-L1 Biomarker Testing Market Size by Country (2020-2025) & (US$ Million)
Table 36. North America PD-L1 Biomarker Testing Market Size by Country (2026-2031) & (US$ Million)
Table 37. Europe PD-L1 Biomarker Testing Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 38. Europe PD-L1 Biomarker Testing Market Size by Country (2020-2025) & (US$ Million)
Table 39. Europe PD-L1 Biomarker Testing Market Size by Country (2026-2031) & (US$ Million)
Table 40. Asia-Pacific PD-L1 Biomarker Testing Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 41. Asia-Pacific PD-L1 Biomarker Testing Market Size by Region (2020-2025) & (US$ Million)
Table 42. Asia-Pacific PD-L1 Biomarker Testing Market Size by Region (2026-2031) & (US$ Million)
Table 43. Latin America PD-L1 Biomarker Testing Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Latin America PD-L1 Biomarker Testing Market Size by Country (2020-2025) & (US$ Million)
Table 45. Latin America PD-L1 Biomarker Testing Market Size by Country (2026-2031) & (US$ Million)
Table 46. Middle East & Africa PD-L1 Biomarker Testing Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 47. Middle East & Africa PD-L1 Biomarker Testing Market Size by Country (2020-2025) & (US$ Million)
Table 48. Middle East & Africa PD-L1 Biomarker Testing Market Size by Country (2026-2031) & (US$ Million)
Table 49. Agilent Technologies Company Details
Table 50. Agilent Technologies Business Overview
Table 51. Agilent Technologies PD-L1 Biomarker Testing Product
Table 52. Agilent Technologies Revenue in PD-L1 Biomarker Testing Business (2020-2025) & (US$ Million)
Table 53. Agilent Technologies Recent Development
Table 54. Roche Company Details
Table 55. Roche Business Overview
Table 56. Roche PD-L1 Biomarker Testing Product
Table 57. Roche Revenue in PD-L1 Biomarker Testing Business (2020-2025) & (US$ Million)
Table 58. Roche Recent Development
Table 59. Merck Company Details
Table 60. Merck Business Overview
Table 61. Merck PD-L1 Biomarker Testing Product
Table 62. Merck Revenue in PD-L1 Biomarker Testing Business (2020-2025) & (US$ Million)
Table 63. Merck Recent Development
Table 64. Bristol-Myers Squibb Company Details
Table 65. Bristol-Myers Squibb Business Overview
Table 66. Bristol-Myers Squibb PD-L1 Biomarker Testing Product
Table 67. Bristol-Myers Squibb Revenue in PD-L1 Biomarker Testing Business (2020-2025) & (US$ Million)
Table 68. Bristol-Myers Squibb Recent Development
Table 69. AstraZeneca Company Details
Table 70. AstraZeneca Business Overview
Table 71. AstraZeneca PD-L1 Biomarker Testing Product
Table 72. AstraZeneca Revenue in PD-L1 Biomarker Testing Business (2020-2025) & (US$ Million)
Table 73. AstraZeneca Recent Development
Table 74. Ono Pharmaceutical Company Details
Table 75. Ono Pharmaceutical Business Overview
Table 76. Ono Pharmaceutical PD-L1 Biomarker Testing Product
Table 77. Ono Pharmaceutical Revenue in PD-L1 Biomarker Testing Business (2020-2025) & (US$ Million)
Table 78. Ono Pharmaceutical Recent Development
Table 79. Regeneron Company Details
Table 80. Regeneron Business Overview
Table 81. Regeneron PD-L1 Biomarker Testing Product
Table 82. Regeneron Revenue in PD-L1 Biomarker Testing Business (2020-2025) & (US$ Million)
Table 83. Regeneron Recent Development
Table 84. Innovent Company Details
Table 85. Innovent Business Overview
Table 86. Innovent PD-L1 Biomarker Testing Product
Table 87. Innovent Revenue in PD-L1 Biomarker Testing Business (2020-2025) & (US$ Million)
Table 88. Innovent Recent Development
Table 89. Hengrui Medicine Company Details
Table 90. Hengrui Medicine Business Overview
Table 91. Hengrui Medicine PD-L1 Biomarker Testing Product
Table 92. Hengrui Medicine Revenue in PD-L1 Biomarker Testing Business (2020-2025) & (US$ Million)
Table 93. Hengrui Medicine Recent Development
Table 94. Junshi Biosciences Company Details
Table 95. Junshi Biosciences Business Overview
Table 96. Junshi Biosciences PD-L1 Biomarker Testing Product
Table 97. Junshi Biosciences Revenue in PD-L1 Biomarker Testing Business (2020-2025) & (US$ Million)
Table 98. Junshi Biosciences Recent Development
Table 99. Research Programs/Design for This Report
Table 100. Key Data Information from Secondary Sources
Table 101. Key Data Information from Primary Sources
Table 102. Authors List of This Report


List of Figures
Figure 1. PD-L1 Biomarker Testing Picture
Figure 2. Global PD-L1 Biomarker Testing Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global PD-L1 Biomarker Testing Market Share by Type: 2024 VS 2031
Figure 4. PD-L1 (22C3) Features
Figure 5. PD-L1(28-8) Features
Figure 6. PD-L1 (SP142) Features
Figure 7. PD-L1 (SP263) Features
Figure 8. Other Features
Figure 9. Global PD-L1 Biomarker Testing Market Size by Application (2020-2031) & (US$ Million)
Figure 10. Global PD-L1 Biomarker Testing Market Share by Application: 2024 VS 2031
Figure 11. Hospital Case Studies
Figure 12. Diagnostic Center Case Studies
Figure 13. Others Case Studies
Figure 14. PD-L1 Biomarker Testing Report Years Considered
Figure 15. Global PD-L1 Biomarker Testing Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 16. Global PD-L1 Biomarker Testing Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 17. Global PD-L1 Biomarker Testing Market Share by Region: 2024 VS 2031
Figure 18. Global PD-L1 Biomarker Testing Market Share by Players in 2024
Figure 19. Global PD-L1 Biomarker Testing Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 20. The Top 10 and 5 Players Market Share by PD-L1 Biomarker Testing Revenue in 2024
Figure 21. North America PD-L1 Biomarker Testing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. North America PD-L1 Biomarker Testing Market Share by Country (2020-2031)
Figure 23. United States PD-L1 Biomarker Testing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Canada PD-L1 Biomarker Testing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Europe PD-L1 Biomarker Testing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. Europe PD-L1 Biomarker Testing Market Share by Country (2020-2031)
Figure 27. Germany PD-L1 Biomarker Testing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. France PD-L1 Biomarker Testing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. U.K. PD-L1 Biomarker Testing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Italy PD-L1 Biomarker Testing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Russia PD-L1 Biomarker Testing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Ireland PD-L1 Biomarker Testing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Asia-Pacific PD-L1 Biomarker Testing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Asia-Pacific PD-L1 Biomarker Testing Market Share by Region (2020-2031)
Figure 35. China PD-L1 Biomarker Testing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Japan PD-L1 Biomarker Testing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. South Korea PD-L1 Biomarker Testing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Southeast Asia PD-L1 Biomarker Testing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. India PD-L1 Biomarker Testing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Australia & New Zealand PD-L1 Biomarker Testing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Latin America PD-L1 Biomarker Testing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Latin America PD-L1 Biomarker Testing Market Share by Country (2020-2031)
Figure 43. Mexico PD-L1 Biomarker Testing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Brazil PD-L1 Biomarker Testing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Middle East & Africa PD-L1 Biomarker Testing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Middle East & Africa PD-L1 Biomarker Testing Market Share by Country (2020-2031)
Figure 47. Israel PD-L1 Biomarker Testing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Saudi Arabia PD-L1 Biomarker Testing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. UAE PD-L1 Biomarker Testing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. Agilent Technologies Revenue Growth Rate in PD-L1 Biomarker Testing Business (2020-2025)
Figure 51. Roche Revenue Growth Rate in PD-L1 Biomarker Testing Business (2020-2025)
Figure 52. Merck Revenue Growth Rate in PD-L1 Biomarker Testing Business (2020-2025)
Figure 53. Bristol-Myers Squibb Revenue Growth Rate in PD-L1 Biomarker Testing Business (2020-2025)
Figure 54. AstraZeneca Revenue Growth Rate in PD-L1 Biomarker Testing Business (2020-2025)
Figure 55. Ono Pharmaceutical Revenue Growth Rate in PD-L1 Biomarker Testing Business (2020-2025)
Figure 56. Regeneron Revenue Growth Rate in PD-L1 Biomarker Testing Business (2020-2025)
Figure 57. Innovent Revenue Growth Rate in PD-L1 Biomarker Testing Business (2020-2025)
Figure 58. Hengrui Medicine Revenue Growth Rate in PD-L1 Biomarker Testing Business (2020-2025)
Figure 59. Junshi Biosciences Revenue Growth Rate in PD-L1 Biomarker Testing Business (2020-2025)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
Choose Your Edition
Add to cart

Our team would be happy to assist you with your queries.

Contact us

About us

Accurate data, The latest market trends, And deeper research directions.

Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals

Latest reports

Useful links

Our Contacts

Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China

(+86) 159 1069 5232

sales@hengceresearch.com
hengceresearch.com

Allow cookies